Fosmidomycin sodium salt (Synonyms: FR-31564)|cas 66508-37-0|DC Chemicals

Cas No.:	66508-37-0
Chemical Name:	FOSMIDOMYCIN, SODIUM SALT
Synonyms:	FOSMIDOMYCIN, SODIUM SALT;Fosmidomycin (sodium salt);sodium,3-[formyl(hydroxy)amino]propyl-hydroxyphosphinate
SMILES:	[Na+].O=CN(CCCP([O-])(O)=O)O
Formula:	C₄H₉NNaO₅P
M.Wt:	205.081493139267
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Fosmidomycin sodium salt is a phosphonic acid antibiotic and a antimalarial drug, which is active against both Gram-negative and Gram-positive bacteria.
In Vivo:	Animals treated intraperitoneally with dosages of >10 mg/kg of fosmidomycin are apparently free of parasites. After treatment with 5 mg/kg of fosmidomycin, parasitemias are <1%. Animals treated orally with 50 or 100 mg/kg of fosmidomycin are apparently free of parasites, and parasitemias are <1% after treatment with 20 mg/kg of drug. Recrudescence is observed when the treatment is terminated after 4 days. Mice treated with 30 mg/kg of fosmidomycin over a period of 8 days are totally cured[3].
In Vitro:	Fosmidomycin sodium salt is a phosphonic acid antibiotic[1][2], which is active against both Gram-negative and Gram-positive bacteria[3].
References:	[1]. Kojo H, et al. FR-31564, a new phosphonic acid antibiotic: bacterial resistance and membrane permeability. J Antibiot (Tokyo). 1980 Jan;33(1):44-8. [2]. Fernandes JF, et al. Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials. Future Microbiol. 2015;10(8):1375-90. [3]. Jomaa H, et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science. 1999 Sep 3;285(5433):1573-6.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.